Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FibroGen, Inc.
  6. News
  7. Summary
    FGEN   US31572Q8087

FIBROGEN, INC.

(FGEN)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/18 12:31:11 pm
10.895 USD   -1.31%
09/23JOHN CHEN : Stock Futures -3-
DJ
09/22FIBROGEN : Goldman Sachs Downgrades FibroGen to Sell Rating From Neutral, Adjusts Price Target to $11 From $16
MT
09/17INSIDER SELL : Fibrogen
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FibroGen : Receives $120 Million Milestone Payment With Approval of Evrenzo in Europe

08/20/2021 | 03:47am EDT


© MT Newswires 2021
All news about FIBROGEN, INC.
09/23JOHN CHEN : Stock Futures -3-
DJ
09/22FIBROGEN : Goldman Sachs Downgrades FibroGen to Sell Rating From Neutral, Adjusts Price Ta..
MT
09/17INSIDER SELL : Fibrogen
MT
09/14COURT OF APPEAL UPHOLDS VALIDITY OF : FibroGen Inc v Akebia Therapeutics Inc EWCA Civ 12..
AQ
08/27FIBROGEN INC : Change in Directors or Principal Officers (form 8-K)
AQ
08/25FIBROGEN : Says Mid-Stage Trial of Potential Anemia Drug Meets Primary Efficacy Endpoint
MT
08/25FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat f..
GL
08/25FibroGen, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadu..
CI
08/23NORTH AMERICAN MORNING BRIEFING : Stock Furures -4-
DJ
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
More news
Analyst Recommendations on FIBROGEN, INC.
More recommendations
Financials (USD)
Sales 2021 261 M - -
Net income 2021 -238 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,14x
Yield 2021 -
Capitalization 1 023 M 1 023 M -
Capi. / Sales 2021 3,92x
Capi. / Sales 2022 4,32x
Nbr of Employees 599
Free-Float 91,8%
Chart FIBROGEN, INC.
Duration : Period :
FibroGen, Inc. Technical Analysis Chart | FGEN | US31572Q8087 | MarketScreener
Technical analysis trends FIBROGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 11,04 $
Average target price 20,86 $
Spread / Average Target 88,9%
EPS Revisions
Managers and Directors
Enrique A. Conterno Chief Executive Officer & Director
Juan Graham Chief Financial Officer
James A. Schoeneck Chairman
Michael Martinelli Senior Vice President-Technical Development
Elias Kouchakji Senior VP-Clinical Development & Drug Safety
Sector and Competitors
1st jan.Capi. (M$)
FIBROGEN, INC.-70.23%1 023
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414